StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.35+0.10 (+8.00%)

Close on Nov 17, 2026Market cap $172.35MP/E –Yield –

ADC Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ADC Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$100.52M. For fiscal 2025 it was -$141.17M. The highest annual figure on record is -$118.69M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$141.17M–
FY2024Dec 31, 2024-$123.84M–
FY2023Dec 31, 2023-$118.69M–
FY2022Dec 31, 2022-$138.31M–
FY2021Dec 31, 2021-$233.38M–
FY2020Dec 31, 2020-$168.73M–
FY2019Dec 31, 2019-$121.58M–
FY2018Dec 31, 2018-$121.36M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$27.88M–
Q2 FY2026Jun 30, 2026-$11.81M–
Q1 FY2026Mar 31, 2026-$29.71M–
Q4 FY2025Dec 31, 2025-$31.12M–
Q3 FY2025Sep 30, 2025-$29.63M–
Q2 FY2025Jun 30, 2025-$24.09M–
Q1 FY2025Mar 31, 2025-$56.33M–
Q4 FY2024Dec 31, 2024-$21.85M–
Q3 FY2024Sep 30, 2024-$25.04M–
Q2 FY2024Jun 30, 2024-$32.85M–
Q1 FY2024Mar 31, 2024-$44.10M–
Q4 FY2023Dec 31, 2023-$31.63M–
Q3 FY2023Sep 30, 2023-$36.67M-1770.8%
Q2 FY2023Jun 30, 2023-$34.99M–
Q1 FY2023Mar 31, 2023-$15.39M–
Q4 FY2022Dec 31, 2022-$53.61M–
Q3 FY2022Sep 30, 2022$2.20M–
Q2 FY2022Jun 30, 2022-$53.01M–
Q1 FY2022Mar 31, 2022-$33.88M–
Q4 FY2021Dec 31, 2021-$61.63M–
Q3 FY2021Sep 30, 2021-$58.59M–
Q2 FY2021Jun 30, 2021-$58.01M–
Q1 FY2021Mar 31, 2021-$55.15M–
Q4 FY2020Dec 31, 2020-$51.69M–
Q3 FY2020Sep 30, 2020-$44.29M–
Q2 FY2020Jun 30, 2020-$40.65M–
Q1 FY2020Mar 31, 2020-$32.10M–

More ADC Therapeutics figures

See a number that looks wrong?